Related Experiment Video
Updated: Feb 17, 2026
08:02
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
3.1K
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Abhishek D Garg1, Sanket More1, Nicole Rufo1
1Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
Oncoimmunology
|December 7, 2017
Summary
Immunogenic cell death (ICD) promotes T cell responses against cancer antigens. This review covers recent advances in ICD-inducing chemotherapy regimens and their clinical evaluation using immune biomarkers.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Immunogenic cell death (ICD) is a form of cell death that enhances T cell-dependent immune responses.
- ICD involves the release of damage-associated molecular patterns (DAMPs) that stimulate adaptive immunity.
- Several established chemotherapeutics, including doxorubicin and oxaliplatin, can induce ICD.
Purpose of the Study:
- To review recent developments in chemotherapeutic regimens designed to induce ICD.
- To focus on studies assessing the clinical efficacy of ICD-inducing agents.
- To highlight the role of immunological biomarkers in evaluating ICD-related therapies.
Main Methods:
- Literature review of recent clinical studies on ICD-inducing chemotherapies.
- Analysis of studies correlating clinical outcomes with immunological markers.
- Focus on specific chemotherapeutic agents and treatment regimens.
Main Results:
- Progress has been made in developing and testing novel ICD-inducing chemotherapy combinations.
- Clinical efficacy is increasingly evaluated alongside immunological responses.
- Biomarkers are crucial for understanding and optimizing ICD-based cancer treatments.
Conclusions:
- ICD-inducing chemotherapies represent a promising strategy for enhancing anti-tumor immunity.
- Further research is needed to fully elucidate the clinical potential of ICD in cancer therapy.
- Integration of immunological monitoring is essential for advancing ICD-based treatment paradigms.
Keywords:
antigen-presenting cellautophagycytotoxic T lymphocytedamage-associated molecular patterndendritic cellendoplasmic reticulum stressimmune checkpoint blockertype I interferonMore Related Videos
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
01:30Overview of Cell Death
10.4K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
10.4K
01:17The Extrinsic Apoptotic Pathway
8.8K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
8.8K
01:31The Intrinsic Apoptotic Pathway
8.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.7K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K